| review article | Q7318358 |
| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P356 | DOI | 10.1002/14651858.CD002290.PUB3 |
| P8608 | Fatcat ID | release_7kfavfbgcrhkdov6rup6n2pgnq |
| P698 | PubMed publication ID | 18254005 |
| P50 | author | Jonathan Craig | Q38591193 |
| P2093 | author name string | Elisabeth M Hodson | |
| Narelle S Willis | |||
| P2860 | cites work | Non-corticosteroid treatment for nephrotic syndrome in children | Q24246970 |
| Measuring inconsistency in meta-analyses | Q27860655 | ||
| Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials | Q27860735 | ||
| Disseminated autoimmune disease during levamisole treatment of nephrotic syndrome | Q28371709 | ||
| Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? | Q29619328 | ||
| Immunosuppressive agents in childhood nephrotic syndrome: a meta-analysis of randomized controlled trials | Q34229368 | ||
| Non-corticosteroid treatment for nephrotic syndrome in children. | Q34424754 | ||
| The treatment of relapsing primary nephrotic syndrome in children | Q34425396 | ||
| Controlled trial of disodium cromoglycate in prevention of relapse of steroid-responsive nephrotic syndrome of childhood | Q34986276 | ||
| Long-term outcome of primary nephrotic syndrome | Q35116114 | ||
| Eight and 12 week courses of cyclophosphamide in nephrotic syndrome | Q35625194 | ||
| Efficacy of mycophenolate mofetil in pediatric patients with steroid-dependent nephrotic syndrome. | Q36155384 | ||
| Identifying relevant studies for systematic reviews | Q36888457 | ||
| The treatment of minimal change nephrotic syndrome: lessons learned from multicentre co-operative studies | Q37733852 | ||
| Comparative trial of 2 weeks and 8 weeks cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood | Q39519150 | ||
| An evidence based approach to individualising treatment | Q41849533 | ||
| Chlorambucil treatment of frequently relapsing nephrotic syndrome | Q41876445 | ||
| Controlled trial of azathioprine in treatment of steroid-responsive nephrotic syndrome of childhood | Q42040029 | ||
| A controlled prospective study of cyclophosphamide in relapsing, corticosteroid-responsive, minimal-lesion nephrotic syndrome in childhood | Q42234441 | ||
| Side effects of levamisole in children with nephrosis | Q42562781 | ||
| A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children | Q43588188 | ||
| Mycophenolate mofetil therapy in frequently relapsing steroid-dependent and steroid-resistant nephrotic syndrome of childhood: current status and future directions | Q43604565 | ||
| Chlorambucil dosage in frequently relapsingnephrotic syndrome: A controlled clinical trial | Q43734767 | ||
| Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome | Q44679612 | ||
| Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil | Q44749406 | ||
| Pulse cyclophosphamide therapy in steroid-dependent nephrotic syndrome | Q44795809 | ||
| High-dose oral cyclosporin therapy for recurrent focal segmental glomerulosclerosis in children | Q44947442 | ||
| Concomitant administration of cyclosporine and ketoconazole in idiopathic nephrotic syndrome. | Q44967473 | ||
| Cyclophosphamide in the treatment of focal segmental glomerulosclerosis | Q45034706 | ||
| Levamisole in steroid-sensitive nephrotic syndrome of childhood: the lost paradise? | Q45066117 | ||
| Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome | Q46488621 | ||
| Long-term results of two unconventional agents in steroid-dependent nephrotic children | Q46621343 | ||
| Experience with levamisole in frequently relapsing, steroid-dependent nephrotic syndrome | Q46750610 | ||
| Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus | Q46823230 | ||
| Therapeutic effect of chai-ling-tang (sairei-to) on the steroid-dependent nephrotic syndrome in children | Q47212166 | ||
| Time trends and ethnic patterns of childhood nephrotic syndrome in Yorkshire, UK. | Q52862093 | ||
| Randomized versus historical controls for clinical trials. | Q52875105 | ||
| Use of levamisole in maintaining remission in steroid-sensitive nephrotic syndrome in children. | Q54220207 | ||
| Cyclosporin in the treatment of idiopathic nephrotic syndrome in children. | Q54399716 | ||
| Evaluation of alternate-day steroid therapy for nephrotic syndrome in childhood by cross-over study | Q54759120 | ||
| Controlled trial of cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood | Q67233964 | ||
| Unconjugated hyperbilirubinemia due to ciclosporin administration in children with nephrotic syndrome | Q67999598 | ||
| Comparison of cyclosporin and chlorambucil in the treatment of steroid-dependent idiopathic nephrotic syndrome: a multicentre randomized controlled trial. The French Society of Paediatric Nephrology | Q68058964 | ||
| Intravenous immunoglobulin in minimal change nephrotic syndrome: a crossover trial | Q68544263 | ||
| Comparison of different regimens of prednisone therapy in frequently relapsing nephrotic syndrome | Q68771343 | ||
| Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft für Pädiatrische Nephrologie | Q69463260 | ||
| Therapeutic and toxic effects observed with different dosage programs of cyclophosphamide in treatment of steroid-responsive but frequently relapsing nephrotic syndrome | Q69503848 | ||
| Controlled trial of azathioprine in children with nephrotic syndrome. A report for the international study of kidney disease in children | Q70134569 | ||
| Effect of cytotoxic drugs in frequently relapsing nephrotic syndrome with and without steroid dependence | Q70215303 | ||
| Consensus statement on management and audit potential for steroid responsive nephrotic syndrome. Report of a Workshop by the British Association for Paediatric Nephrology and Research Unit, Royal College of Physicians | Q72295857 | ||
| Long-term cyclosporin A treatment of minimal-change nephrotic syndrome of childhood | Q72771725 | ||
| A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome | Q73969343 | ||
| A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome | Q79331373 | ||
| 164 children with nephrosis | Q79336530 | ||
| Idiopathic nephrotic syndrome in New Zealand children, demographic, clinical features, initial management and outcome after twelve-month follow-up: results of a three-year national surveillance study | Q80297759 | ||
| Is tacrolimus for childhood steroid-dependent nephrotic syndrome better than ciclosporin A? | Q83347988 | ||
| Sterility and testicular atrophy related to cyclophosphamide therapy | Q93716977 | ||
| Cyclophosphamide and the pubertal testis | Q93731659 | ||
| P921 | main subject | nephrotic syndrome | Q504790 |
| P577 | publication date | 2008-01-23 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Non-corticosteroid treatment for nephrotic syndrome in children |
| Q34836338 | A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment |
| Q38863081 | A single-centre retrospective study of the safety and efficacy of mycophenolate mofetil in children and adolescents with nephrotic syndrome |
| Q39712811 | Calcineurin inhibitor induced nephrotoxicity in steroid resistant nephrotic syndrome |
| Q87402193 | Chapter 3: Steroid-sensitive nephrotic syndrome in children |
| Q83602331 | Clinical course and outcome of children with steroid-sensitive nephrotic syndrome |
| Q53625850 | Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy. |
| Q84459052 | Cyclophosphamide followed by mizoribine as maintenance therapy against refractory steroid-dependent nephrotic syndrome |
| Q83587128 | Cyclophosphamide in steroid-dependent nephrotic syndrome |
| Q50202874 | Effectiveness and nephrotoxicity of a 2-year medium dose of cyclosporine in pediatric patients with steroid-dependent nephrotic syndrome: determination of the need for follow-up kidney biopsy |
| Q84944158 | Effects of cyclosporine on bone mineral density in patients with glucocorticoid-dependent nephrotic syndrome in remission |
| Q92401273 | Efficacy and acceptability of immunosuppressive agents for pediatric frequently-relapsing and steroid-dependent nephrotic syndrome: A network meta-analysis of randomized controlled trials |
| Q38021391 | Is cyclophosphamide effective in patients with IgM-positive minimal change disease? |
| Q92816853 | Levamisole in Children with Idiopathic Nephrotic Syndrome: Clinical Efficacy and Pathophysiological Aspects |
| Q83602335 | Long-term follow-up after cyclophosphamide therapy in steroid-dependent nephrotic syndrome |
| Q51529212 | Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial. |
| Q56962909 | Mycophenolate mofetil for sustained remission in nephrotic syndrome |
| Q37202763 | Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome |
| Q35185376 | Nephrotic syndrome in children: from bench to treatment |
| Q38854254 | Nephrotoxicity in children with frequently relapsing nephrotic syndrome receiving long-term cyclosporine treatment |
| Q37828086 | New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome |
| Q24202861 | Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children |
| Q37812564 | Pathogenesis and therapy of focal segmental glomerulosclerosis: an update |
| Q37709168 | Pharmacotherapeutic review and update of idiopathic nephrotic syndrome in children. |
| Q35972218 | Population pharmacokinetics of levamisole in children with steroid-sensitive nephrotic syndrome |
| Q85523101 | Prediction of steroid-sparing agent use in childhood idiopathic nephrotic syndrome |
| Q57945954 | References |
| Q37330330 | Risk factors for cyclosporin A nephrotoxicity in children with steroid-dependant nephrotic syndrome |
| Q35113681 | Rituximab Treatment for Nephrotic Syndrome in Children |
| Q33555088 | Rituximab for nephrotic syndrome in children. |
| Q39440837 | Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials. |
| Q38075787 | Rituximab therapy in nephrotic syndrome: implications for patients' management |
| Q84951697 | Short-term efficacy of rituximab versus tacrolimus in steroid-dependent nephrotic syndrome |
| Q37108328 | Single dose of rituximab in children with steroid-dependent minimal change nephrotic syndrome |
| Q35233125 | Steroid-sensitive nephrotic syndrome in children: triggers of relapse and evolving hypotheses on pathogenesis |
| Q87204226 | Substantial practice variation exists in the management of childhood nephrotic syndrome |
| Q38000020 | The contribution of systematic reviews to the practice of pediatric nephrology |
| Q91974244 | The safety and efficacy of mycophenolate mofetil in children and adolescents with steroid-dependent nephrotic syndrome: a single-centre study |
| Q35226744 | Treatment of steroid and cyclosporine-resistant idiopathic nephrotic syndrome in children. |
| Q38050961 | Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. |
| Q24234648 | Tripterygium wilfordii Hook F (a traditional Chinese medicine) for primary nephrotic syndrome |
| Q36810492 | Two-year outcome of the ISKDC regimen and frequent-relapsing risk in children with idiopathic nephrotic syndrome |
Search more.